Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE JenaValve Technology, Inc.
Unique Technology, Design Represent Competitive Advantage
WILMINGTON, Del. and MUNICH, Oct. 15, 2013 /PRNewswire/ -- JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the most promising private companies in the medical device industry in 2013. JenaValve was chosen as one of the Fierce 15 based, in part, on the innovation and promise of the JenaValve TAVI System.
"JenaValve and the other Fierce 15 companies we chose represent some of the best and brightest in the device and diagnostic industries today," FierceMedicalDevices Editor Damian Garde said. "They'll be producing big things in the months ahead."
The global market for TAVI systems is expected to grow to more than $3 billion in 2016.
Last month, the JenaValve TAVI System was granted CE (Conformite Europeenne) Mark approval from European regulators for its transapical TAVI system for the treatment of aortic insufficiency (AI), a condition also known as aortic regurgitation in which the native aortic valve does not close properly, allowing blood to leak back into the left ventricle of the heart. The JenaValve is now approved for the entire range of aortic valve disease - from severely calcified to not calcified at all – and is the only TAVI device worldwide approved for the treatment of high-risk or inoperable patients suffering from severe aortic insufficiency.
"We are encouraged that medical device editors in the US are recognizing the value of the JenaValve TAVI System, and even more important, the large and growing patient population that can now benefit from our proprietary devices," said JenaValve CEO Helmut J. Straubinger. "Our unique technology and the design of our valve are our competitive advantages. We are looking forward to expanding our commercial footprint in new geographies around the world."
Transcatheter aortic valve implantation (TAVI) systems produce in excess of $1 billion in annual revenues worldwide and the market is expected to grow to more than $3 billion in 20161. Clinicians are now increasingly focused on TAVI technical and procedural refinements and advancements found in next-generation products such as JenaValve's that address and resolve issues including ease of implantation, the need for post-procedure pacemaker implantation and post-implant paravalvular leakage.
About the JenaValve TAVI System
The JenaValve is a true second-generation catheter-based aortic valve implantation system engineered and manufactured to the highest quality standards. The JenaValve transapical TAVI system is currently being sold in Europe and other markets around the world. The Company's transfemoral TAVI system is expected to enter into clinical study in late 2013 and is anticipated to be available for sale in 2014.
About JenaValve Technology
JenaValve Technology, Inc., a U.S. corporation with primary operations in Munich, Germany, develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. JenaValve was founded in 2006 by cardiologists and inventors Prof. Hans R. Figulla, M.D. and Prof. Markus Ferrari, M.D. The Company's transapical aortic valve system is CE marked and currently marketed in Europe and other markets worldwide. JenaValve is backed by world-class U.S., European and Asian investors: Atlas Venture, Edmond de Rothschild Investment Partners, NeoMed Management, VI Partners, Sunstone Capital, GIMV, Legend Capital and Omega Funds. Additional information is available at www.jenavalve.com
European Contact: JenaValve Technology GmbH, Guerickestr. 25, 80805 Munich (Germany) +498955279080 or firstname.lastname@example.org
U.S. Contact: Matt Clawson, Allen & Caron Inc. 949.474.4300 or Matt@allencaron.com
1) Goldman Sachs Global Investment Research
©2012 PR Newswire. All Rights Reserved.
Can't find what you're looking for?